^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

ROS1 G2032R + ROS1 L2086F

i
Other names: ROS1, ROS Proto-Oncogene 1 Receptor Tyrosine Kinase, V-Ros Avian UR2 Sarcoma Virus Oncogene Homolog 1, C-Ros Oncogene 1 Receptor Tyrosine Kinase, Proto-Oncogene Tyrosine-Protein Kinase ROS, Proto-Oncogene C-Ros-1, MCF3, ROS, V-Ros UR2 Sarcoma Virus Oncogene Homolog 1 (Avian), ROS Proto-Oncogene 1 Receptor Tyrosine Kinase, Transmembrane Tyrosine-Specific Protein Kinase, Receptor Tyrosine Kinase C-Ros Oncogene 1, C-Ros Receptor Tyrosine Kinase, Proto-oncogene C-Ros, C-Ros-1
Entrez ID:
over1year
A Phase 2 Study of Lorlatinib in Patients With ROS1-Rearranged Lung Cancer With Brain-Only Progression on Crizotinib. (PubMed, JTO Clin Res Rep)
No grade greater than or equal to 4 adverse events were observed. Lorlatinib induced durable intracranial responses in patients with ROS1-rearranged NSCLC and prior isolated CNS progression on crizotinib.
P2 data • Journal
|
RET (Ret Proto-Oncogene) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • CCDC6 (Coiled-Coil Domain Containing 6)
|
RET fusion • ROS1 fusion • CCDC6-RET fusion • ROS1 rearrangement • ROS1 G2032R • ROS1 L2086F • ROS1 G2032R + ROS1 L2086F
|
Xalkori (crizotinib) • Lorbrena (lorlatinib)
2years
Phase II Study of Lorlatinib in Patients with ROS1-Rearranged Lung Cancer with CNS Progression on Crizotinib (IASLC-TTLC 2022)
No grade 5 adverse events were observed. The study was terminated early after enrollment of 16 of 22 planned patients due to the commercial availability of off-label lorlatinib.Conclusion s : The CNS-penetrant next-generation ROS1 inhibitor lorlatinib is an effective salvage therapy for patients experiencing isolated CNS progression on crizotinib.
Clinical • P2 data
|
RET (Ret Proto-Oncogene) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • CCDC6 (Coiled-Coil Domain Containing 6)
|
RET fusion • ROS1 fusion • CCDC6-RET fusion • ROS1 rearrangement • ROS1 G2032R • ROS1 L2086F • ROS1 G2032R + ROS1 L2086F
|
Xalkori (crizotinib) • Lorbrena (lorlatinib)